| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2020: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2019: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2018: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Outline of Final Research Achievements |
A therapeutic drug for dilated cardiomyopathy was searched for by drug repositioning of existing drugs. Candidate drugs were selected by in vitro screening using iPS cell-derived cardiomyocytes, and efficacy and safety were evaluated using a hamster model of spontaneous dilated cardiomyopathy. As a result, it was shown that 6 of the existing drugs are effective against the decrease in cardiac function associated with the onset of dilated cardiomyopathy. It was also shown that a synergistic effect can be expected by administering these in combination.
|
